All In Biotech

Drug Trial Radar · NCT02665065

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplant Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (AML)

Last checked: Nov 19, 2026Latest source record: Jul 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Title says "pivotal". Randomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

153

Actual

Start

Jun 2016

Primary completion

Jun 2022

Study completion Dec 2026

Sponsor

Lead sponsor
Actinium PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 27, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia (AML).

Conditions

  • Acute Myeloid Leukemia
  • Leukemia, Acute Myeloid
  • Myeloid Leukemia, Acute
  • Leukemia, Myeloid, Acute
  • Acute Myelogenous Leukemia
  • Leukemia, Acute Myelogenous
  • Myelogenous Leukemia, Acute
  • AML
  • Bone Marrow Transplant

Interventions

  • Iomab-BDrug

  • Conventional CareDrug

  • HCTProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Durable Complete Remission (dCR)Time frame: 6 months from time of initial CR or CRp

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Yale Cancer Center

    New Haven, Connecticut

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Mayo Clinic

    Jacksonville, Florida

  • Loyola University Medical Center

    Maywood, Illinois

  • University of Iowa

    Iowa City, Iowa

  • The University of Kansas Cancer Center

    Westwood, Kansas

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Weill Cornell Medicine

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Stony Brook University

    Stony Brook, New York

  • University of North Carolina Hospital

    Chapel Hill, North Carolina

  • University Hospital of Cleveland Seidman Cancer Center

    Cleveland, Ohio

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • University of Ottawa

    Ottawa, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.